This article refers to simple isocratic reverse-phase high-performance liquid chromatographic method (RP-HPLC) developed for the simultaneous quantification of Escitalopram Oxalate (EST) and Clonazepam (CZP) in active pharmaceutical ingredient and pharmaceuticals. The separation of the two drugs was attained using a C₁₈ column (250mm×4.6mm, 5µ) as a stationary phase. The mobile phase was used as a mixture of methanol; acetonitrile; and 0.05M potassium dihydrogen orthophosphate buffer (pH 4 adjusted by orthophosphoric acid) with an isocratic ratio of 40:20:40 v/v. Detection was made by using PDA detector at 210 nm. Escitalopram Oxalate (RT= 4.428 minutes) and Clonazepam (RT= 6.532 minutes) were separated in a single chromatographic run with resolution of 8.719. The calibration plot indicated good linear relationship with r 2 = 0.998 for Escitalopram Oxalate in concentration range of 32 µg/ml -48 µg/ml and r 2 = 0.999 for Clonazepam in concentration range of 16 µg/ml -24 µg/ml. The retrievals for Escitalopram Oxalate and Clonazepam were found to be 99.75% and 99.00%, respectively. The established analytical method was validated and found acceptable as per ICH guidelines for linearity, precision, accuracy, specificity, limit of detection, limit of quantification, robustness and stability. Escitalopram Oxalate and Clonazepam individually as well as in combination were exposed to different stress conditions like acid, base, thermal, photolytic and oxidation degradation and peaks of a degraded product were well determined from peaks of pure drug. This method is modest, quick and appropriate for routine quality control analysis.
INTRODUCTION

Escitalopram oxalate (EST) (
) is chemically known as S-(+)-1-[3-(dimethyl-amino) propyl]-1-(p-fluro-phenyl)-5-phthalancarbonitrile oxalate, which fits to the class of compounds known as antidepressant and is the Senantiomer of racemic citalopram 1 . Escitalopram is spontaneously soluble in dimethlysulfoxide (DMSO), methanol and, sparingly soluble in ethanol and water. Escitalopram is insoluble in heptane but slightly soluble in ethyl acetate.
Escitalopram oxalate originates in category of oral selective serotonin reuptake inhibitor (SSRI) and proved highly potent with in vitro and in vivo studies. Escitalopram mainly used for the management of generalized Anxiety Disorder and major depressive disorder. Escitalopram works by specific competitive inhibition of the membrane transporter of serotonin 2 . As per studies Escitalopram discovered to be more than twice as potent as citalopram and is the highly selective drug in its class [2] [3] .Several analytical methods have been developed for the estimation of escitalopram oxalate in pharmaceutical formulations and/or biological fluids include liquid chromatography coupled with mass spectrometry 4 . Figure 1b ) is a derivative of benzodiazepine related to diazepam, with distinct antiepileptic properties 5 . It is official in BP 6 and USP 7 .
Chemically clonazepam is 5-(2-chlorophenyl)-1, 3-dihydro-7-nitro-2H-1,4-benzodiazepine-2-one. Clonazepam is a light yellow crystalline powder that is practically odorless. It is freely very soluble in acetone, ethanol and methanol and insoluble in water.
Clonazepam is known as commercial drug to treat the depression associated with anxiety and highly used for the treatment of seizure and anxiety disorders. It works by Allosteric interactions between gamma-aminobutyric acid (GABA) receptors and central benzodiazepine receptors and potentiate the effects of GABA. GABA being an inhibitory neurotransmitter, helps to increase inhibition of the ascending reticular activating system (RAS) 8 .
The literature survey reveals the accessibility of analytical methods for the quantitative estimation of Escitalopram Oxalate (EST) and Clonazepam (CZP) individually, or combination of these drugs with other drugs typically using chromatographic methods with different detectors such as electrochemical 9 or mass spectrometry detection [10] [11] [12] fluorescence 13 , gas chromatography with electron-capture 14 or mass spectrometry 15 detection. The present study describes the development and validation of a stability indicating RP-HPLC method for the simultaneous estimation of EST and CZP in active pharmaceutical ingredient and marketed tablet formulation. The developed method was effectively applied for the routine analysis of EST and CZP in bulk and marketed tablet formulation.
MATERIAL AND METHOD
Standards of Escitalopram Oxalate and Clonazepam and marketed formulations were received as a gift sample from Consern Pharma Pvt. Ltd., Sahnewal, Punjab, India. All the chemical, solvents and reagents were HPLC and analytical grade procured from Merck chemicals, Mumbai, India. Water purified via milli-Q 0.45 µ Millipore nylon filter. The marketed formulation (ESTax Plus) used for analysis was procured from Consern Pharma Pvt. Ltd., Sahnewal, Punjab, India.
Instrumentation and chromatographic conditions:
Analysis was performed on a Shimadzu HPLC (LC-2010) equipped with Prominence LC-Gradient quaternary pump (LC-20AD), auto sampler, online degasser, sampler cooler and a SPD-20A prominence PDA detector. Operation data acquisition and analysis were performed by using LC solution software. The analytical column C₁₈ column (250mm×4.6mm, 5µ) was used for separation. The isocratic elution was done with mobile phase of acetonitrile; methanol; and 0.05M potassium dihydrogen orthophosphate buffer (pH 4 adjusted by orthophosphoric acid) with an isocratic ratio of 40:20:40 v/v. Detection was performed by using PDA detector at 210 nm. The flow rate of 1.0 ml min -1 and created a back pressure of approx. 1039 psi. The buffer for mobile phase was prepared by dissolving 2.72 Potassium di-hydrogen orthophosphate in 400 ml of water and the pH was adjusted to 4 (±0.1) with orthophosphoric acid. Mobile phase was filtered through 0.45µ Millipore nylon filter under vacuum and ultrasonicated for 10 minutes prior use. The column was maintained at 35 0 C temperature, detection was carried out using PDA detector at 210 nm and injection volume of 20 µl was used for analysis.
Standard solutions and calibration graphs for standardization:
For Stock standard solutions, 100 mg EST and 50 mg CZP working standard were separately weighed and transferred into 100 ml volumetric flasks respectively. Further, 60 ml of mobile phase was added in both volumetric flasks and sonicated for 5 minutes and the volume was made with mobile phase. Aliquots of standard sub-stock solutions (1ml) of EST and CZP were pipette out accurately in 25 ml volumetric flask and standard concentration of 40µg/ml and 20µg/ml were prepared respectively using mobile phase.
Sample preparation:
Sample was prepared by weighing accurately 20 tablets of combination of EST & CZP in pastel mortar and crushed. Weigh accurately sample powder about equivalent to 1/20 mg of CZP/EST and transfer them to 50ml of volumetric flask. The samples were sonicated for 10 minutes with 5ml of water and then add 30 ml of mobile phase and shake to dissolve and make volume with Mobile Phase. The above sample solutions were filtered through 0.45µ Millipore nylon filter paper and used for estimation. 
Method validation: System Suitability Test:
The system suitability test was conducted to calculate the accuracy of the system for the analysis, using six replicate injection of a reference solution of EST and CZP. The parameters measured were number of theoretical plates, retention time, peak area and tailing factor.
Specificity:
Specificity is the ability of the method to estimate the response of the analyte in the presence of its degradation products and potential impurities. The quantity of drugs was determined by taking chromatograms by using appropriate dilutions [16] [17] [18] [19] [20] [21] [22] [23] [24] .
Linearity and range:
Calibration curves were prepared by plotting concentrations versus peak area of EST and CZP. It was verified from 80% to 120% of standards concentration using five calibration levels of 80%, 90%, 100%, 110 %, and 120%, (i.e. 32,36,40,44 and 48 μg/ml for EST and 16,18,20,22 and 24 μg/ml for CZP). For evaluation of data, method of linear regression was used [16] [17] [18] [19] [20] [21] [22] [23] [24] .
Precision:
Three replicates of standard solution using with different concentrations were used for Precision analysis of the analytical method. It was demonstrated by intermediate precision (interday precision) and repeatability (intraday precision) of the solutions [16] [17] [18] [19] [20] [21] [22] [23] [24] .
Accuracy:
It is measure of closeness of experimental values to the true value. The previous analyzed samples of EST/CZP (10mg/0.5mg) were spiked with extra 50%, 100% and 150% of the standard EST/CZP, and the proposed method was used for re-analysis of mixtures. The experiment was
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[267] CODEN (USA): JDDTAO conducted in triplicate. RSD (%) and standard error mean (%) were calculated for each concentration. The recovery of the drug was ensured at different levels in the formulations 23 .
Limit of detection (LOD) and Limit of Quantitation (LOQ):
The limit of detection (LOD) and limit of quantification (LOQ) were used to describe the smallest concentration of an analyte that can be reliably measured by an analytical procedure as per ICH guidelines. By using the visual evaluation method, LOD was estimated by constant detection of the analyte at the minimum level. LOQ's were expressed as the minimum concentration of standard analytes that can be reproducibly calculated with acceptable precision and accuracy.
Robustness:
Robustness of the analytical method referred to its ability to remain unaffected by minute, but deliberate changes alterations in method parameters 16 . Robustness was studied by analyzing the effect of small and deliberate changes made in chromatographic conditions like, temperature of column, flow rate, pH and composition of mobile phase 25 .
Assay of marketed preparation:
The prepared sample preparations of EST and CZP were tested on HPLC and percentage assay was calculated using following formulas.
For EST:
Area 
Alkali Hydrolysis:
Standards of EST (100mg) and CZP (100mg) were accurately weighed and transferred into three 1N NaOH was added to all flasks and refluxed on heated mantle for 60 min at 80 O C 24 .
Oxidative Degradation:
Standards of EST (100mg) and CZP (100mg) were accurately weighed and transferred into three sets of 250ml round bottom flasks. About 20ml of 6% H2O2 was added to all flasks and refluxed on heated mantle for 2 hr. at 80 O C 24 .
Thermal Degradation:
Standard of EST (100mg) and CZP (100mg) was accurately weighed and transferred into Petri dish individually and spread into thin layer with spatula; this Petri dish was placed in the hot air oven for 1 hour at 80 O C. Heated drug samples of EST (100mg) and CZP (100mg) were taken into 100ml volumetric flask and dissolved in diluent. Volume was made up to the mark using diluent. 1ml of above sample was transferred into 10 ml volumetric flask and diluted up to the mark using diluent. It was filtered through 0.45µ Millipore nylon filter and filtrate was used for chromatographic analysis 24 .
Photolytic Degradation:
Standard of EST (100mg) and CZP (100mg) was accurately weighed and transferred into petri dish individually and spread into thin layer with spatula; this petri-dish was put inside the UV Chamber for 1 hour. UV-exposed drugs samples of EST (100mg) and CZP (100mg) were taken into 100ml volumetric flask, and dissolved in diluent. Volume was made up to the mark using diluent. 1ml of above sample was taken into 10ml volumetric flask in a few ml of mobile phase and sonicated for 10min; this solution was cooled to the room temperature and made up the volume up to the mark using mobile phase. It was filtered through 0.45µ Millipore nylon filter and filtrate was used for chromatographic analysis 24 .
RESULTS AND DISCUSSION
Method Optimization:
In the current study, separation of two analytes was carried out using Reversed-phase LC-method. Mobile phase used in study consist of mixture of organic solvents i.e. methanol: acetonitrile and aqueous buffer. Firstly, the column used was a C₁₈ column (250mm×4.6mm, 5µ) as a stationary phase. The mobile phase was used as a mixture of acetonitrile; methanol; and 0.05M potassium dihydrogen orthophosphate buffer with an isocratic ratio of 40:30:30 v/v. Detection was performed by using PDA detector at 210 nm. The flow rate was maintained at 0.8 ml/minute which does not show enough resolution between analytes. After that, another column was used a C₁₈ column (250mm×4.6mm, 5µ) as a stationary phase. The mobile phase was used as a mixture of acetonitrile; methanol; and 0.05M potassium dihydrogen orthophosphate buffer (pH 4 adjusted by orthophosphoric acid) with an isocratic ratio of 40:20:40 v/v. Detection was performed by using PDA detector at 210 nm. that showed adequate resolution between EST and CZP. To optimize the chromatographic parameters, the effect on changing the composition and pH (range from pH 3-6) of mobile phase was studied on the peak asymmetry, theoretical plates, retention time, capacity factor (k') and resolution. 
Method Validation:
Method validation is the proof needed to ensure that an analytical method can produce results which are reliable and reproducible and which are fit for the purpose intended. The parameters that need to be demonstrated are system suitability test, precision, accuracy, specificity, linearity and range, limit of detection and limit of quantification and robustness as per ICH guidelines. The system suitability test was performed to ensure the adequacy, validity and feasibility of the analytical method with instrument and also ensures the resolution between peaks of different analytes. The system suitability tests was applied to a representative chromatogram to confirm the various parameters such as peak area, peak asymmetry, capacity factor, theoretical plates, resolution, retention time and repeatability of the chromatographic system and ensures that the equipment, electronics and analytical operations for the samples analyzed could be constituted as an integral system that can be evaluated as a whole. The RSD of peak areas of five consecutive injections was found to less than 2%, as 1.28 % for EST and 1.05% for CZP, thus showing good repeatability, and excellent chromatographic and environmental conditions ( Table 1 ). The resolution between the peaks of analytes indicates good separation from each other, as resolution found to be greater than 2. Theoretical plate number (N) and capacity factor (k´) demonstrated good column efficiency (Figure 2 ).
Specificity:
The specificity of a method demonstrates the presence of impurities or excipient. Specificity was determined by injecting placebo preparation, diluents, standard solution and sample preparation. No peak was interfering with retention time of analyte peaks ( Figure 3 ). This clearly indicates that, excipients don't interfere with analytes and the assay is specific for EST and CZP.
Linearity and range:
The linearity of an analytical procedure is its ability (within a range) to obtain test results which are directly proportional to the concentration (amount) of analyte in the sample. The linearity range is 32 µg/ml to 48 µg/ml for EST with a correlation coefficient of 0.9998 and 16 µg/ml to 24 µg/ml for CZP with a correlation coefficient of 0.999 (Figure 4 ). The linearity of EST and CZP was found to be in range. The precision of an analytical procedure is the spreading of results from a replicates sets of measurements. The precision, was studied by calculating the RSD value. The intermediate precision composed of two parameters:
intraday ( = 6) and interday ( = 6). The RSD values of intraday precision was 0.284 and 1.965 for EST and CZP, respectively and of interday precision was 0.168 and 1.442 for EST and CZP, respectively ( Table 2 ). The RSD value for intermediate precision was found to be <2%, which confirms that the proposed method is précised. The accuracy of the analytical procedure expresses the closeness of mean values for a replicate set of a result to the true or accepted value. It can also be termed as trueness. The accuracy was assessed by the recovery experiments that were performed by the standard addition method. The recoveries obtained were 99.75 and 99.00 for EST and CZP, respectively (Table 3) . Recovery between 80-120% indicates that the developed analytical method is accurate for determination of pharmaceuticals on combinations.
Limit of detection (LOD) and Limit of Quantitation (LOQ):
The LOD and LOQ were determined from slops of linear regression curves. LOD and LOQ were found to be 0.028 and 0.079 g/ml for EST and 0.015 and 0.092 g/ml for CZP respectively (Table 4) . 
Robustness:
Robustness of analytical method refers to its ability to remain unaffected when subjected to small changes in method parameters. The method was determined by deliberately varying parameter like flow rate and pH of mobile phase used for estimation (Table 5 ). Assay of EST and CZP as tablet in comparison to standard:
The validated method was applied for the simultaneous quantification of these drugs in the marketed formulation and the percentage assay of EST was found to be 99.01% and for CZP found to be 99.57% in comparison to the standard of both drugs (Table 6 ).This clearly justify the assay in between 90-110% of the label claim. 
Forced degradation study (Stability study):
Forced degradation study plays a key role in development of stability indicating method. This study justified useful information about the degradation pathway of drug substances and drug products that could be form during storage. It was concluded by performing stress testing that the method was specific for EST and CZP. Both drugs were observed to be highly unstable for acidic, basic conditions while CZP is stable in oxidative stress conditions in comparison to EST, which is still unstable as per current study. So, under these conditions, we should be very careful during analysis. Hence, special storage conditions should be provided for the dosage form. The chromatograms of individual drugs as well as in combination after force degradation study under various stress conditions are shown in Figures 5-9 . The percentage assay and percentage degradation of both EST and CZP observed for current degradation study is mentioned in Table 7 in comparison to assay values of EST and CZP without degradation (Table 6) . The validated results showed that this method was specific, sensitive, linear, precise, accurate and robust. It can be concluded that this newly developed RP-HPLC method can be successfully applied for routine analysis for the estimation of combination of EST and CZP in tablet as well as bulk dosage form in pharmaceutical industry. Degradation studies justified the method specificity for its intended application. Therefore, the proposed method can be used for routine analysis of two drugs in their combined pharmaceutical dosage form.
